Icosagen is participating in the development of inhalable vaccines led by ISR Vaccine AB in Sweden targeting SARS-CoV-2 and other respiratory viruses such as influenza and RSV.

The lead candidate, the dry powder nasal vaccine for SARS-CoV-2, has reached Phase I/II clinical trials. The first-in-human study is conducted with 150 volunteers at two qualified study sites in Dhaka, Bangladesh. Vaccine and infection naïve volunteers will be randomized to receive 2 vaccine doses or placebo 4 weeks apart. The study subjects will be monitored for safety in addition to specific T cell and immunoglobulin immune responses.